Boston, MA – July 2, 2025 — Receptor.AI, a leading AI-driven drug discovery company, announces that Professor Morten Meldal, laureate of the 2022 Nobel Prize in Chemistry, has joined the company as Scientific Advisor.

Professor Meldal is internationally recognized for co-developing the copper-catalyzed azide-alkyne cycloaddition (CuAAC), a foundational reaction in click chemistry. His work has influenced multiple areas of modern chemistry, including peptide synthesis and molecular design. He currently leads the Center for Evolutionary Chemical Biology at the University of Copenhagen and has authored over 300 scientific papers and 21 patents.

At Receptor.AI, Professor Meldal will contribute his expertise in chemistry and molecular design to support the advancement of research across peptide and small molecule drug discovery.

“Professor Meldal’s expertise will strengthen the scientific foundation of our company,” said Dr. Alan Nafiiev, CEO of Receptor.AI. “We look forward to working together on improving our approaches to structure-based design and experimental integration.”

His involvement reflects Receptor.AI’s continued focus on combining domain expertise with AI-driven drug design to support efficient and reliable drug discovery.

About Receptor.AI

Receptor.AI is a TechBio company advancing AI-navigated drug discovery. Receptor.AI has developed a robust, validated drug discovery ecosystem tailored to address complex protein targets, comprising three core platforms:

• Small Molecule Platform: Target, indication, and MoA-specific design of small molecules using validated AI-based and data-driven workflows.
• Peptides Platform: AI-guided de novo design and optimization of linear and cyclic peptides against challenging targets, including “undruggable” protein-protein interactions.
• Induced Proximity Platform: Transforming structurally unresolved native and induced PPIs into druggable targets with ternary complexes assembly.

Built on extensive experience and over 40 successful joint discovery projects, Receptor.AI’s multiplatform ecosystem empowers researchers to design small molecules, peptides, and induced proximity agents with unprecedented accuracy. By focusing on validated R&D strategies and modular workflows that integrate seamlessly into existing R&D processes, Receptor.AI has become a trusted partner to big pharma companies and academic institutions worldwide. For further information, please visit the company’s website at receptor.ai. 

Press & Media Inquiries

• Receptor.AI
  Tetiana Skakun, Marketing Operations Specialist
  tetiana.skakun@receptor.ai